At the news
? BEARISHIMPACT 8/10 S-4/A filed Sep 2, 2026 at 21:44 ET
Passage Bio filed an amended S-4 (S-4/A) detailing its proposed reverse merger with Remix Therapeutics, where Remix will become a wholly owned subsidiary and Passage Bio will change its name to Remix Therapeutics, Inc. Pre-merger Passage Bio equity holders are expected to own approximately 6% of the combined company, while Remix equity holders and concurrent financing investors are expected to own approximately 65% and 29%, respectively. The concurrent financing, via a Subscription Agreement and convertible notes, is expected to raise approximately $100 million in gross proceeds, with the closing conditioned on the merger, and Passage Bio's remaining assets from its GM1 and MLD programs are being packaged into contingent value rights (CVRs) for current Passage Bio stockholders that may expire worthless.
- Pre-merger Passage Bio equity holders will own approximately 6% of the combined company; Remix equity holders ~65%, concurrent financing investors ~29%.
- Concurrent financing expected to raise ~$100.0 million, but is conditioned on merger closing.
- Passage Bio equity holders will receive one CVR per share for proceeds from Gemma Biotherapeutics license arrangements (GM1 and MLD), which may expire worthless.
- Passage Bio's net cash at closing is anticipated to be approximately $10.9 million, but its valuation for the exchange ratio is based on an assumed $5.0 million net cash; Passage Bio's net cash is nearly fully depleted beyond immediate obligations.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access